Barclays PLC reduced its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 91.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,942 shares of the company's stock after selling 125,931 shares during the period. Barclays PLC's holdings in Ginkgo Bioworks were worth $98,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new stake in shares of Ginkgo Bioworks in the second quarter valued at about $2,128,000. XTX Topco Ltd purchased a new position in shares of Ginkgo Bioworks during the 2nd quarter worth $312,000. Benjamin F. Edwards & Company Inc. increased its position in shares of Ginkgo Bioworks by 1,606.9% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 234,836 shares of the company's stock valued at $79,000 after acquiring an additional 221,078 shares during the last quarter. AQR Capital Management LLC purchased a new stake in Ginkgo Bioworks in the second quarter valued at approximately $3,391,000. Finally, Mackenzie Financial Corp purchased a new stake in shares of Ginkgo Bioworks in the 2nd quarter valued at $251,000. Institutional investors and hedge funds own 78.63% of the company's stock.
Ginkgo Bioworks Stock Down 3.2 %
NYSE:DNA traded down $0.42 on Friday, reaching $12.76. 1,580,885 shares of the company's stock were exchanged, compared to its average volume of 1,434,739. The stock has a market cap of $733.44 million, a price-to-earnings ratio of -0.98 and a beta of 1.09. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $5.26 and a 52-week high of $64.40. The business has a fifty day simple moving average of $9.49.
Ginkgo Bioworks Profile
(
Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Read More
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
